/ALGEN.PA

ALGEN.PA Stock - genOway S.A.

Q: What is the analyst price target for ALGEN.PA?

Analyst price target information is not currently available for ALGEN.PA.

Q: What is ALGEN.PA's market cap?

Market capitalization information is not currently available for ALGEN.PA.

Healthcare|Biotechnology|PAR

$2.60-0.00%

$0.00 (-0.00%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.86

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ALGEN.PA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.55

52W High$3.97

52W Low$2.10

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$22.06M	$20.05M	$17.05M	$14.02M	$11.02M
Gross Profit	$-1,885,344	$18.80M	$-1,310,109	$-3,746,365	$-2,959,904
Gross Margin	-8.5%	93.8%	-7.7%	-26.7%	-26.9%
Operating Income	$1.81M	$2.07M	$949,835	$-4,594,748	$-3,838,700
Net Income	$1.83M	$1.57M	$777,752	$-322,598	$-687,302
Net Margin	8.3%	7.8%	4.6%	-2.3%	-6.2%
EPS	$0.19	$0.17	$0.09	$-0.04	$-0.10

Company Overview

genOway Société anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and immune checkpoint catalog cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was founded in 1999 and is headquartered in Lyon, France.

Visit Website